Status:
UNKNOWN
Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas
Lead Sponsor:
Ruijin Hospital
Conditions:
Non-hodgkin Lymphoma,B Cell
Eligibility:
All Genders
18+ years
Brief Summary
Describe the treatment of B-cell non-Hodgkin lymphoma patients who receive lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs), and evaluate the efficacy and...
Detailed Description
This is a multi-center prospective, observational real-world study, targeting patients with B-cell non-Hodgkin's lymphomas. This study is designed to evaluate the efficacy and safety of lenalidomide s...
Eligibility Criteria
Inclusion
- Diagnosed as B-cell non-Hodgkin's lymphoma
- Voluntary participation in this study and the signing of an informed consent form
- The researchers assessed that the patient will benefit from the treatment of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs)
Exclusion
- Contradictions to any drug in the treatment regimen
- Pregnant or lactating women
- Patients who were not considered suitable for the study by the researchers
Key Trial Info
Start Date :
November 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04435743
Start Date
November 1 2019
End Date
December 1 2022
Last Update
July 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Ruijin Hospital
Shanghai, China